According to Milestone Scientific's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.803. At the end of 2022 the company had a P/E ratio of -4.00.
Year | P/E ratio | Change |
---|---|---|
2022 | -4.00 | -80.58% |
2021 | -20.6 | 16.6% |
2020 | -17.7 | 90.65% |
2019 | -9.27 | 489.7% |
2018 | -1.57 | -77.36% |
2017 | -6.94 | 4.12% |
2016 | -6.67 | -29.08% |
2015 | -9.40 | -66.07% |
2014 | -27.7 | -237.57% |
2013 | 20.1 | -168.14% |
2012 | -29.6 | 720.87% |
2011 | -3.60 | -85.88% |
2010 | -25.5 | 65.41% |
2009 | -15.4 | 450.6% |
2008 | -2.80 | -58.82% |
2007 | -6.80 | 59.65% |
2006 | -4.26 | -23.39% |
2005 | -5.56 | 3.08% |
2004 | -5.39 | -9.23% |
2003 | -5.94 | 296.19% |
2002 | -1.50 | -1.82% |
2001 | -1.53 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.